Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024

L. Antunes, C. Mazagatos, I. Martínez-Baz, R. Naesens, ML. Borg, G. Petrović, T. Fatukasi, L. Jancoriene, A. Machado, B. Oroszi, P. Husa, M. Lazar, R. Dürrwald, J. Howard, A. Melo, G. Pérez-Gimeno, J. Castilla, E. Bernaert, A. Džiugytė, ZL....

. 2024 ; 18 (8) : e13360. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019435

Grantová podpora
ECDC/2021/016 European Centre for Disease Prevention and Control

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

Cantacuzino National Military Medical Institute for Research and Development Bucharest Romania

Clinic of Infectious Diseases and Dermatovenerology Institute of Clinical Medicine Medical Faculty Vilnius University Vilnius Lithuania

Consortium for Biomedical Research in Epidemiology and Public Health Madrid Spain

Croatian Institute of Public Health Zagreb Croatia

Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany

Department of Infectious Diseases Lithuanian University of Health Sciences Kaunas Lithuania

Department of Medical Microbiology and Infection Prevention and Control Ziekenhuisnetwerk Antwerpen Antwerp Belgium

Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest Romania

Epidemiology Department Epiconcept Paris France

Epidemiology Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

European Centre for Disease Prevention and Control Stockholm Sweden

Health Service Executive Health Protection Surveillance Centre Dublin Ireland

Infectious Disease Prevention and Control Unit Health Promotion and Disease Prevention Msida Malta

Infectious Diseases Department National Health Institute Doutor Ricardo Jorge Lisbon Portugal

Instituto de Salud Pública de Navarra IdiSNA Pamplona Spain

National Centre for Epidemiology Institute of Health Carlos 3 Madrid Spain

National Laboratory for Health Security Epidemiology and Surveillance Centre Semmelweis University Budapest Hungary

National Reference Centre for Influenza Robert Koch Institute Berlin Germany

University Hospital Brno Masaryk University Brno Czechia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019435
003      
CZ-PrNML
005      
20241024110719.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/irv.13360 $2 doi
035    __
$a (PubMed)39145535
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Antunes, Liliana $u Epidemiology Department, Epiconcept, Paris, France $1 https://orcid.org/0000000304535304
245    10
$a Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024 / $c L. Antunes, C. Mazagatos, I. Martínez-Baz, R. Naesens, ML. Borg, G. Petrović, T. Fatukasi, L. Jancoriene, A. Machado, B. Oroszi, P. Husa, M. Lazar, R. Dürrwald, J. Howard, A. Melo, G. Pérez-Gimeno, J. Castilla, E. Bernaert, A. Džiugytė, ZL. Makarić, M. Fitzgerald, A. Mickienė, V. Gomez, G. Túri, L. Součková, A. Marin, K. Tolksdorf, N. Nicolay, AMC. Rose, European Hospital Vaccine Effectiveness Group
520    9_
$a We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
650    _2
$a lidé $7 D006801
650    12
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    12
$a COVID-19 $x prevence a kontrola $x epidemiologie $7 D000086382
650    12
$a vakcíny proti COVID-19 $x imunologie $x aplikace a dávkování $7 D000086663
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a SARS-CoV-2 $x imunologie $7 D000086402
650    12
$a účinnost vakcíny $x statistika a číselné údaje $7 D000087507
650    12
$a vakcinace $x statistika a číselné údaje $7 D014611
650    _2
$a mladý dospělý $7 D055815
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a mladiství $7 D000293
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Mazagatos, Clara $u National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $1 https://orcid.org/0000000269096923
700    1_
$a Martínez-Baz, Iván $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain $1 https://orcid.org/0000000234052277
700    1_
$a Naesens, Reinout $u Department of Medical Microbiology and Infection Prevention & Control, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium $1 https://orcid.org/0000000310047737
700    1_
$a Borg, Maria-Louise $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta
700    1_
$a Petrović, Goranka $u Croatian Institute of Public Health, Zagreb, Croatia $1 https://orcid.org/0000000183045519
700    1_
$a Fatukasi, Terra $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland $1 https://orcid.org/0000000332871831
700    1_
$a Jancoriene, Ligita $u Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000164886312
700    1_
$a Machado, Ausenda $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal $1 https://orcid.org/0000000218491499
700    1_
$a Oroszi, Beatrix $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000189150336
700    1_
$a Husa, Petr $u University Hospital Brno, Masaryk University, Brno, Czechia $1 https://orcid.org/0000000291902610 $7 xx0018127
700    1_
$a Lazar, Mihaela $u Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania $1 https://orcid.org/0000000282266026
700    1_
$a Dürrwald, Ralf $u National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany $1 https://orcid.org/0000000234320438
700    1_
$a Howard, Jennifer $u Epidemiology Department, Epiconcept, Paris, France $1 https://orcid.org/0009000819308693
700    1_
$a Melo, Aryse $u Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal $1 https://orcid.org/0000000266558715
700    1_
$a Pérez-Gimeno, Gloria $u National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $1 https://orcid.org/0000000334354854
700    1_
$a Castilla, Jesús $u Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain $u Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain $1 https://orcid.org/0000000263967265
700    1_
$a Bernaert, Eva $u Department of Medical Microbiology and Infection Prevention & Control, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium
700    1_
$a Džiugytė, Aušra $u Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta $1 https://orcid.org/0000000304868491
700    1_
$a Makarić, Zvjezdana Lovrić $u Croatian Institute of Public Health, Zagreb, Croatia $1 https://orcid.org/0000000342852116
700    1_
$a Fitzgerald, Margaret $u Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland $1 https://orcid.org/0000000245350966
700    1_
$a Mickienė, Auksė $u Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania
700    1_
$a Gomez, Verónica $u Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal $1 https://orcid.org/0000000304850005
700    1_
$a Túri, Gergő $u National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000334658321
700    1_
$a Součková, Lenka $u University Hospital Brno, Masaryk University, Brno, Czechia $1 https://orcid.org/0000000300284464
700    1_
$a Marin, Alexandru $u Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania $1 https://orcid.org/0009000076689607
700    1_
$a Tolksdorf, Kristin $u Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany $1 https://orcid.org/0000000287126399
700    1_
$a Nicolay, Nathalie $u European Centre for Disease Prevention and Control, Stockholm, Sweden $1 https://orcid.org/0000000259167855
700    1_
$a Rose, Angela M C $u Epidemiology Department, Epiconcept, Paris, France $1 https://orcid.org/0000000224938082
710    2_
$a European Hospital Vaccine Effectiveness Group
773    0_
$w MED00157838 $t Influenza and other respiratory viruses $x 1750-2659 $g Roč. 18, č. 8 (2024), s. e13360
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39145535 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110713 $b ABA008
999    __
$a ok $b bmc $g 2201960 $s 1231408
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 18 $c 8 $d e13360 $e - $i 1750-2659 $m Influenza and other respiratory viruses $n Influenza Other Respir Viruses $x MED00157838
GRA    __
$a ECDC/2021/016 $p European Centre for Disease Prevention and Control
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace